Pharmacologic Treatments for COVID-19

During corona virus, the FDA has issued an emergency use authorization (EUA) for bamlanivimab, which is a monoclonal antibody given against the spike protein of SARS-CoV-2

Baricitinib or JAK inhibitor is used in combination with remdesivir, in the treatment of suspected or laboratory-confirmed coronavirus disease in hospitalized patients aged 2 years and elderly who require supplemental oxygen, invasive mechanical ventilation. Various other antiviral agents, immunotherapies, and vaccines continue to be investigated and developed as possible therapies.

Committee Members
Speaker at Pharmaceutics and Drug Delivery Systems 2021 - Sergey Suchkov

Sergey Suchkov

Sechenov University and Moscow Engineering Physical Institute, Russian Federation
Speaker at Pharmaceutics and Drug Delivery Systems 2021 - Marino Nebuloni

Marino Nebuloni

Parma University, Italy
Speaker at Pharmaceutics and Drug Delivery Systems 2021 - Esmaiel Jabbari

Esmaiel Jabbari

University of South Carolina, United States
Speaker at Pharmaceutics and Drug Delivery Systems 2021 - Paul Millner

Paul Millner

University of Leeds, United Kingdom
PDDS 2021 Speakers
Speaker at Pharmaceutics and Drug Delivery Systems 2021 - Jan Versijpt

Jan Versijpt

University Hospital Brussels, Belgium
Speaker at Pharmaceutics and Drug Delivery Systems 2021 - Madhav Bhatia

Madhav Bhatia

University of Otago, New Zealand
Speaker at Pharmaceutics and Drug Delivery Systems 2021 - Stefanie Santos

Stefanie Santos

University Hospital Zurich, Switzerland
Speaker at Pharmaceutics and Drug Delivery Systems 2021 - Dmitry Ustyuzhanin

Dmitry Ustyuzhanin

National Medical Research Center of Cardiology, Russian Federation
Speaker at Pharmaceutics and Drug Delivery Systems 2021 - Anna Caprifico

Anna Caprifico

Kingston University, United Kingdom
Speaker at Pharmaceutics and Drug Delivery Systems 2021 - Annalisa Dalmoro

Annalisa Dalmoro

University of Salerno, Italy

Submit your abstract Today

Watsapp